Journal of Enzyme Inhibition and Medicinal Chemistry (Dec 2023)

Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues

  • Marta Pichlak,
  • Tomasz Sobierajski,
  • Katarzyna M. Błażewska,
  • Edyta Gendaszewska-Darmach

DOI
https://doi.org/10.1080/14756366.2023.2254012
Journal volume & issue
Vol. 38, no. 1

Abstract

Read online

AbstractPROTACs represent an emerging field in medicinal chemistry, which has already led to the development of compounds that reached clinical studies. Posttranslational modifications contribute to the complexity of proteomes, with 2846 disease-associated sites. PROTAC field is very advanced in targeting kinases, while its use for enzymes mediating posttranslational modifications of the basic amino acid residues, started to be developed recently. Therefore, we bring together this less popular class of PROTACs, targeting lysine acetyltransferases/deacetylases, lysine and arginine methyltransferases, ADP-ribosyltransferases, E3 ligases, and ubiquitin-specific proteases. We put special emphasis on structural aspects of PROTAC elements to facilitate the lengthy experimental endeavours directed towards developing PROTACs. We will cover the period from the inception of the field, 2017, to April 2023.

Keywords